Objective: β-catenin is one of the most critical oncogenes associated with many kinds of human cancers, especially in the human CRC. Innate immunity recognizes tumour derived damage-associated molecular patterns (DAMPs) and primes the antitumour adaptive responses. While the function of β-catenin in CRC tumourigenesis is well established, its impact on innate immune evasion is largely unknown. The aim of this study is to characterize the role of β-catenin in inhibiting RIG-I-like receptor (RLR)-mediated IFN-β signalling in colorectal cancer.
| INTRODUC TI ON
The highly conserved β-catenin protein, the vertebrate's homologue of Drosophila armadillo, is one of the most frequent protooncogenes. β-catenin is composed of 781 amino acids which forms 12 armadillo repeats. It is widely expressed in normal tissues, such as cardiac muscle, and aberrantly overexpressed in various human cancers including colorectal, hepatocellular, lung, breast, ovarian and endometrial cancers.
1 Among these cancers, the tumourigenic role of β-catenin-mediated activation of the canonical WNT signalling pathway which passes signals into a cell through cell surface receptors and then leads to regulation of gene transcription, is well recognized in human CRC. 2, 3 In addition, β-catenin also participates in the regulation of other signalling pathways, such as NF-κB signalling and TGF-β signalling. 4, 5 Recently, emerging evidences suggested that β-catenin was also involved in the regulation of innate and adaptive immunity in mouse liver injury. 6 All of these observations prompted us to hypothesize that β-catenin might regulate immune responses during CRC development.
Immune surveillance plays crucial roles in controlling tumourigenesis and cancer progression. 7, 8 An important aspect of malignant tumour progression is the immune evasion. Tumour cells are able to escape from the detection and destruction by the adaptive arms of the immune system through numerous strategies, including the downregulation of MHC molecules, the secretion of immune suppressive molecules like PD-L1 and so on. can recognize damage or pathogen-associated molecular patterns (PAMPs). 11 Tumour associating nucleotides or metabolites will be sensed by PRRs including the RIG-I-like receptor (RLR) family which can recognize double-stranded RNA or single-stranded RNA, 12 the membrane-associated Toll-like receptors (TLRs) 13 which can recognize different double-stranded RNA or single-stranded RNA internalized into the endosomes of specified cells, 7 and more importantly, DNA sensors including cGAS and DAI, which serve as cytosolic sensors for microbial DNA or leaking DNA from tumours. [14] [15] [16] Once activated upon recognition, these pattern-recognition receptors will trigger the downstream signalling cascades that result in a rapid production of type I interferons and pro-inflammatory cytokines. 17 In the context of cancers, these cytokines will prime and cooperate with adaptive immune responses which together eradicate the abnormal cancer cells. Ample evidences have proved that the type I interferon, interferons-β (IFN-β) directly inhibits tumourigenesis by regulating tumour cell proliferation and apoptosis in human melanoma, hepatocellular carcinoma and breast cancers. [18] [19] [20] The central transcription factor, interferon-regulatory factor 3 (IRF3), is mainly responsible for the induction of interferon-β (IFN-β)
and essential for the activation of interferon responses. 21 Upon detecting the pathogen by PRR, IRF3 is phosphorylated by TBK1
kinase complex and undergoes a rapid conformational change, allowing its homo-dimerization and nuclear translocation where it binds to the interferon-stimulated response elements of the target genes. 22 The important role of IRF3 in the induction of interferon responses suggests that it must be appropriately regulated and "finely tuned" to determine the accurate nature of the final innate immune responses. 23 On the other hand, cancer cells might hijack these regulatory mechanisms or even develop novel strategies to block the interferon responses, in fulfilling the escape of the immune surveillance.
Here, we report a novel function of β-catenin in regulating innate immune responses in CRC. We found that β-catenin negatively regulated the translocation of IRF3 into the nucleus and thus inhibited innate immune responses in CRC. This study expands our understanding on the crosstalk between an oncogene and innate immune responses, and may explain in part the enhanced ability to escape innate immunity in oncogenic transformed colorectal cells. 
| MATERIAL S AND ME THODS

| Cell lines and viruses
| Constructs
Luciferase reporter plasmids for the IFN-β promoter, expression plasmids for RIG-I-N, MAVS, TBK1 and IRF3-5D were described IFN-β and interferon-stimulated gene 56 (ISG56). Mechanistically, we found that β-catenin interacted with IRF3 and blocked its nuclear translocation.
Conclusion:
Our study reveals an unprecedented role of β-catenin in enabling innate immune evasion in CRC. 
| Antibodies and reagents
Antibodies against FLAG (M2, Sigma), β-catenin (H102, Santa Cruz were purchased from the indicated suppliers.
| DNA transfection
For plasmid transfection in HEK293T cells, calcium phosphate transfection method was applied. HEK293T cells were plated at around 50%-60% confluence. 
| Lentivirus-mediated stable cell line construction
| Immunohistochemistry analysis
| Plaque assay
VSV titre was determined by plaque assay on Vero monolayer cells as previously described. 12 Briefly, 10-fold serially-diluted viruscontaining supernatant was added into Vero cells and incubated for 2 hours at 37°C. Then, DMEM containing 2% FBS and 1% methylcellulose (Sigma) was added after removing the supernatant. Plaques were counted at day 3 post-infection.
| Quantitative Real-time PCR (qRT-PCR)
Quantitative Real-time PCR was performed as previously described. 12 Cells were infected or treated with viruses or agents respectively for the indicated time period. Total RNA was ex- 
Reverse 5′-TGACATCTCAATTGCTCCAG-3′
| Luciferase reporter assay
HEK293T cells, seeded in 24-well plates (~50% cell density), were transfected with IFN-β-Luc reporter plasmid cocktail (50 ng of luciferase reporter plasmid and 100 ng of β-galactosidase control vector) and β-catenin by calcium phosphate transfection.
Whole cell lysates were used to determine the activity of firefly luciferase and β-galactosidase by a microplate reader (FLUOstar Omega).
| Immunoblotting
Cells were collected, rinsed with ice-cold PBS and lysed in NP-40 buffer (50 mM Tris-HCl [pH7.4], 150 mM NaCl, 1% NP-40, 5 mM EDTA) supplemented with a protease inhibitor cocktail (Roche) and sonicated for 3 times on ice. Whole cell lysates were denatured and resolved by SDS-PAGE. Proteins were transferred to nitrocellulose membrane and blocked in TBS-T containing 3% non-fat milk for 1 hour at room temperature. Membrane was incubated with primary antibodies (1:1000 dilution) overnight at 4°C. Blots were washed extensively and incubated with corresponding IRDye800 conjugated secondary antibodies (Licor) at 1:10000 for one hour at room temperature. Proteins were visualized using Odyssey infrared imaging system (Licor).
| Co-immunoprecipitation (Co-IP) and immunoblotting
For immunoprecipitation, cells were harvested and whole cell shown for all analyses. We then assessed the expression of β-catenin, the key type I interferon transcription factor IRF3 in different CRC cell lines. The overall expression of β-catenin was high and positively correlated with IRF3 in most of the cell lines ( Figure 1C ). These data prompted us to investigate the correlation between β-catenin and IRF3-mediated innate immune signalling during colorectal tumourigenesis.
| Statistical analysis
| β-catenin disrupts antiviral response in CRC cells
To probe the potential role of β-catenin in IRF3-mediated innate immunity, we used GFP-tagged VSV infection to assess its effect on 
| β-catenin negatively regulates IFN-β production in CRC cells
Interferon beta (IFN-β) signalling, as the major type I interferon signalling, plays utmost roles in the antiviral responses against VSV. 
| β-catenin inhibits RIG-I-like receptor (RLR)-mediated IFN-β signalling pathway in CRC cells
It is well-known that both SeV and VSV are critical inducers of the RIG-I-like receptor (RLR)-mediated IFN-β signalling pathway. 25 As shown in the diagram illustrates the RIG-I-IFN-β signalling pathway ( Figure 4A ), we reasoned that β-catenin ought to inhibit one of the signalling proteins along the RIG-I-IFN-β signalling axis. To identify the target protein, we examined the effect of β-catenin on the IFN-β transcription activity induced by every single RIG-I signalling proteins including RIG-I-2CARD (the 2 caspase activation and recruitment domains of RIG-I which is constitutively active), MAVS, TBK1 and IRF3-5D (a constitutively active IRF3).
26
Interestingly, we found that the activity of the IFN-β reporter was reduced upon overexpression of β-catenin in all the experiment settings, including RIG-I-2CARD, MAVS, TBK1 and IRF3-5D
( Figure 4B,C) . This demonstrated that β-catenin directly targeted the most downstream protein of the RIG-I signalling axis, which was IRF3. To consolidate our finding, we sought out to study the interaction between IRF3 and β-catenin. As shown in coimmunoprecipitation (Co-IP) assay, IRF3 was readily pulled down by exogenously expressed β-catenin in 293T cells ( Figure 4D ) and the endogenous β-catenin in HCT116. Furthermore, the interaction between IRF3 and β-catenin was increased upon SeV infection ( Figure 4E ). These results indicated that β-catenin directly interacted with and exerted an inhibitory effect on IRF3, which explained its negative role in the innate immunity and antiviral responses in CRC cells. β-catenin, as proto-oncogene, has been studied extensively since the discovery of its aberrant various human cancers.
| β-catenin blocks the nuclear translocation of IRF3 in CRC cells
32,33
Here, we report a novel function of β-catenin, which is the inhibition of type I interferon signalling in CRC cells. We propose that β-catenin contributes to the tumour evasion of host recognition and type I innate immune activation. Mechanistically, we demonstrated that β-catenin targets IRF3, the critical transcription factor for IFN-β production. Our study uncovered a novel crosstalk between tumour oncogene and the IRF3-mediated innate immune responses, providing another immunotherapy strategy to boost host immune defence against tumour progression by targeting β-catenin.
From our studies, we found that β-catenin blocked IFN-β production and supported VSV replication. This finding is not unexpected, as β-catenin is the main components of cell cytoskeleton.
Ample evidences have shown that most of components of cytoskeleton, including microfilaments, F-actin, microtubules and intermediate filaments can help virus to evade immunosurveillance of host and benefit to virus assembly and budding. 34 We also noticed that in another paper, the authors fund high level of β-catenin could inhibit viral replication in lung epithelial cells by enhancing the virus-dependent induction of the IFNB1 gene and interferon-stimulated genes. 35 We think that the contradictory It is widely acknowledged that IRF3 is the key transcription factor mainly responsible for the production of IFN-β. The activation of IRF3 contains several essential steps: phosphorylation, homodimerization and nuclear translocation. We found that β-catenin interacted with IRF3 and blocked its nuclear translocation. The binding of β-catenin to IRF3 is also indirectly supported by other studies, in which cytoskeleton microtubules can interact with IRF3. 36 The mechanism beyond this inhibition could be explained by either direct trapping IRF3 in the cytoplasm or blocking its association with TBK1, resulting in failure of phosphorylation and dimerization. Future studies will be needed to characterize the nature of it.
β-catenin is one of commonly mutated or overexpressed oncogenes in CRC. 32, 33 We demonstrated these "high β-catenin" CRC cells had "crippled" production of type I interferon and antiviral responses, and some virus infection can induce the occurrence and development of CRC by enhances CRC cells proliferation, migration and upregulation of EMT markers, 37 thus they might represent Cells were then infected with SeV (100 [HAU]/mL) for the indicated hours. IRF3 nuclear translocation was analysed by immunofluorescence microscopy with anti-IRF3 antibody. (E) The percentage of IRF3 nuclear translocation was calculated based on the immunofluorescence result by ImageJ Software, *P < .01 (Student's t test). Independent experiments were repeated 2 or 3 times immune responses. 38, 39 We speculate that ablation of the production of type I interferon by β-catenin in CRC might further contribute to tumour development. Overall, we consider that β-catenin might exert oncogene activity in part through inhibition of innate immune responses via down regulation of the production of type I interferon in CRC, for its escape of host innate immunity defence. Additionally,
we have expanded β-catenin's repertoire as an oncogene via antagonizing RIG-I-like receptor (RLR)-mediated IFN-β signalling pathway.
Taken together, our findings have revealed the novel function of β-catenin in innate immunity which will benefit the development of efficient immune therapeutic interventions and oncolytic treatment for human CRC.
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